News
AmunBio to Present Scientific Data for AMUN-003 at the 2022 San Antonio Breast Cancer Symposium (SA
EVANSTON, Ill., Nov. 22, 2022 /PRNewswire-PRWeb/ -- AmunBio, Inc., an early, pre-clinical stage biotechnology company focused on developing and commercializing novel engineered immunotherapeutic oncolytic viruses, today announced a presentation, on Tuesday, December 6, 2022, at the 45th annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Tx., of the pre-clinical study results of AMUN-003, an investigational, first-in-class, immuno-oncologic adenovirus being developed for the treatment of multiple solid tumors, including aggressive, metastasized, triple-negative breast cancer (TNBC).
AmunBio and NorthShore to Advance Cancer Immunotherapy...
AmunBio, Inc. and NorthShore University HealthSystem's Research Institute have entered into an exclusive license agreement that allows AmunBio to use a novel platform technology for the development of engineered immunotherapeutic oncolytic viruses for the treatment of hard-to-treat solid tumors. The agreement also includes a research collaboration for the development and commercialization of novel immunotherapeutics.